Articles tagged with Osteoporosis
A recent study reveals significant disparities in osteoporosis treatment among elderly Americans, with men and blacks being undertreated compared to women and whites. The findings highlight the need for improved osteoporosis management strategies that address these disparities.
Researchers found ultrasound of the calcaneus to be equal to DXA data in assessing bone health, paving the way for widespread use of low-cost screenings for populations at risk. The findings support preventive lifestyle changes as the best approach to improving bone health and reducing osteoporosis risk.
Researchers identified a gene defect underlying childhood-onset osteoporosis in two Finnish families and four additional families worldwide. The SGMS2 gene mutation causes changes in bone metabolism and mineralisation, leading to severe short stature and disturbed bone development.
Researchers at Mayo Clinic reviewed health records of 89 people with osteoporosis or osteopenia and found 29 bony injuries, including compression fractures. They recommend modifying yoga poses to accommodate these conditions.
Research published in the Journal of Investigative Medicine found that US older women are three times more likely to receive treatment for osteoporosis than men of similar age. Men aged 80+ were particularly under-screened and undertreated, with only 10-13% having a bone density scan and fewer than 1 in 10 treated with bisphosphonates.
A recent study published by The Endocrine Society found that oral complications are rare in women taking medications for postmenopausal osteoporosis. Despite concerns among dentists and patients, the rate of osteonecrosis of the jaw (ONJ) was low, with only 5.2 cases per 10,000 patient-years reported.
Researchers at Hokkaido University found that inhibiting a bone receptor protein called Siglec-15 can increase bone mass and strength without impairing growth in young rats. This suggests that anti-Siglec-15 therapy could be an alternative treatment for juvenile osteoporosis, potentially with an ideal safety profile.
Researchers have created an atlas of genetic factors associated with estimated bone mineral density, explaining 20% of the genetic variance linked to osteoporosis. The study identifies over 500 genetic determinants, providing promising targets for novel therapeutics to prevent or treat the disease.
Scientists have discovered that irisin, a hormone released by muscles during exercise, directly acts on key regulatory cells that control the breakdown and formation of bone. Treating osteocytes with irisin protected them from age-related death and increased their production of sclerostin, a protein that triggers bone remodeling.
The International Osteoporosis Foundation and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases established recommendations for economic evaluations in osteoporosis. These guidelines aim to improve transparency and methodologic standards, promoting high-quality methodolo...
A large international study confirms measuring bone microarchitecture with new imaging technology accurately predicts risk of fracture in older women and men. The study found that deficits in bone density and structure contribute to fracture risk independently of bone mineral density.
Researchers have determined the three-dimensional structure of the PTH-1 receptor, a protein fragment involved in bone loss. This breakthrough enables the development of new drugs that may slow down or reverse osteoporosis without its current treatment's disadvantages.
The new guidelines review and update the 2013 European guidance for diagnosing and managing osteoporosis in postmenopausal women. Key findings include the importance of evaluating bone microstructure and using FRAX tools in fracture risk assessment, as well as the need for long-term dietary intakes and monitoring drug treatment.
A new imaging process will enable x-ray microscopy on living subjects, facilitating more detailed analysis of bone structure changes in osteoporosis. The European Research Council funds the project with a €12.3 million grant.
A new study found that denosumab improves spinal bone mineral density and reduces pain in patients with osteoporosis caused by transfusion-dependent thalassemia. The treatment also showed promise in increasing bone density in other areas, such as the wrist and femoral neck.
An interdisciplinary team will create a novel X-ray microscope to analyze bone microstructure in living individuals, enabling the study of osteoporosis and its progression. The '4D+ nanoSCOPE' will make it possible to monitor bones over time and assess the effects of aging and other factors on bone health.
A study published in Journal of Bone and Mineral Research found that 8.3% of patients with total hip replacements experienced atypical femoral fractures, a type of rare stress fracture. The researchers also discovered a strong association between bisphosphonate use and the risk of these fractures.
A new study found that cataract patients have a 29% increased risk of developing osteoporosis or fractures compared to healthy controls. Patients who underwent cataract surgery had a 42% lower risk of developing osteoporosis or fracture.
Researchers found that men have a three-fold higher risk of sustaining a secondary fracture within one year of a first fracture compared to women. Engaging in at least moderate physical activity can help reduce this risk and improve bone strength.
The ASBMR Fracture Prevention Initiative Coalition releases new clinical recommendations to tackle the public health crisis of osteoporosis and its debilitating hip and spine fractures. The guidelines aim to increase diagnosis and treatment of high-risk individuals, particularly those over 65 with a history of hip or vertebral fractures.
New studies from UC Davis Health reveal that fractures lead to bone density losses throughout the body, particularly around the time of fracture and in bones far from the site of injury. The research also identifies age-related recovery differences, with younger mice regaining pre-fracture bone mineral density levels.
Hematologic stem cell transplantation (HSCT) survivors are at risk of bone loss and osteoporosis, increasing the likelihood of fragility fractures. The IOF expert Working Group on Cancer and Bone Disease provides clinical guidance for monitoring, evaluation, and treatment of bone loss in these patients.
A recent study published in Nature Communications has identified SIRT7 as a key enzyme in regulating bone formation. The researchers found that SIRT7 deacylates the 368th lysine residue of SP7/Osterix, leading to increased osteoblast differentiation and bone density.
A new expert review outlines the clinical characteristics of bone fragility in adults with diabetes and provides valuable insights for diagnosis and treatment. The review highlights recent studies on bone mineral density, biochemical markers, and fracture prediction to inform clinicians about the optimal approach to managing bone healt...
A new genetic screen developed at Stanford University School of Medicine can predict a person's future risk of osteoporosis and bone fracture. The screen identified 899 regions in the human genome associated with low bone-mineral density, with those deemed high-risk being nearly 17 times more likely to develop osteoporosis.
A Mediterranean-type diet rich in fruits, vegetables, nuts, and olive oil reduced hip bone loss in people with osteoporosis within 12 months. The study, involving over 1,000 participants, showed a significant increase in bone density at the femoral neck. This could be a welcome addition to current drug treatments for osteoporosis.
The USPSTF updates its recommendation on screening for osteoporosis to include bone measurement testing for prevention of osteoporotic fractures in eligible populations. Approximately 12 million individuals in the US older than 50 years are expected to have osteoporosis by 2020.
A recent study found no correlation between circulating bone turnover markers and hip fracture risk among postmenopausal women. The research adds to the existing evidence that these markers are not useful for predicting hip fracture risk.
Researchers developed an improved method for calculating risk for heart attack or stroke, finding that 11 million Americans may need to discuss different prescriptions with their doctor. The new calculations suggest major changes to statin, aspirin, and blood pressure medication prescribing, particularly for African Americans.
A new expert consensus review found that a balanced diet with sufficient protein intake can benefit adult bone health, particularly in seniors with osteoporosis. Adequate calcium intake is crucial to support the benefits of dietary protein on bone density and reduce fracture risk.
A study published in Journal of Bone and Mineral Research found that alendronate reduced the risk of one-year cardiovascular death by 67% and heart attack by 45%. The medication also showed protective effects against stroke, with a 17% reduced risk over 10 years.
A recent study published in The BMJ found that vertebroplasty, a surgical procedure to repair spinal fractures, does not provide significant pain relief for patients with osteoporosis. The trial involved 180 adults and showed no difference in pain scores between those who received vertebroplasty and those who underwent a sham procedure.
Researchers at Hospital for Special Surgery are launching a two-year study to measure the bone effects of secukinumab in men and women with ankylosing spondylitis. The study aims to understand how the drug affects bone metabolism and identify potential benefits for patients with this condition.
A Loyola Medicine study found that 15.4% of osteoporosis patients taking bisphosphonates experienced bone fractures during a six-year follow-up period. Patients at high risk of fracture should be closely followed, especially as the drug holiday lengthens.
A UAB-led study published in The Lancet Diabetes & Endocrinology found that denosumab was superior to risedronate in increasing bone density in patients with glucocorticoid-induced osteoporosis. The 12-month study enrolled 795 patients and showed promising results for the new drug.
The International Osteoporosis Foundation's new interactive map reveals wide global variation in calcium intake, with low levels prevalent in Asia and Latin America. The map highlights the need for public health strategies to increase calcium intake throughout the lifespan.
Professor Cyrus Cooper has been named the winner of the annual Olof Johnell Science Award, recognizing his internationally recognized contributions to the field of osteoporosis. He leads an internationally competitive programme of research into musculoskeletal disorders, most notably osteoporosis.
Professor Nicholas Harvey received the prestigious IOF Medal of Achievement for his outstanding work in understanding early determinants of fracture risk and developing novel interventions. He has made significant contributions to the field of osteoporosis through his research and educational initiatives.
Researchers investigated barriers to advance care planning in prisons, finding profound patient mistrust and obstructive institutional policies. The study also explored the link between hypertension treatment and an increased risk of falls, suggesting that de-intensified blood pressure control may reduce recurrent falls.
A possible treatment for Hajdu-Cheney syndrome has been identified, which may also help with age-related osteoporosis. Researchers found that a medication called DAPT blocks osteoclast formation, reversing bone loss in mice with the disease.
Pooled data from 14 osteoporosis clinical trials indicate that reduced bone turnover markers are associated with lower vertebral fracture risks. The findings may aid in developing anti-resorptive drugs by optimizing dose and treatment schedules.
A new study found that community screening for osteoporosis reduced hip fractures by 28% in older women. Screening identified those at risk and led to targeted treatment, resulting in a significant decrease in hip fractures.
A large multicentre study found that community screening for osteoporosis using bone mineral density measurements and a questionnaire led to a 28% reduction in hip fractures among older women. The approach is estimated to prevent one hip fracture for every 111 women screened.
The FRAX calculator has been widely adopted globally, helping clinicians make informed decisions based on multiple scientifically validated risk factors. A recent study confirms that intervention thresholds based on fracture probabilities are highly effective in targeting high-risk individuals.
A systematic review by the International Osteoporosis Foundation reveals low dietary calcium intake in many Asian and Latin American countries, with the lowest average intake found among China, India, and Indonesia. The study emphasizes the need for increased calcium consumption to promote bone health in these regions.
The IOF Compendium documents the growing global burden of osteoporosis, with projected increases in fractures expected to pose a huge challenge on healthcare systems. The report outlines eight priority actions to stem this burden, including provision of Orthogeriatric and Fracture Liaison Services.
Daily calcium intake among adults varies widely around the world, with many areas at risk of bone health due to low intakes. Regional patterns show Southern and Eastern Asia having the lowest average intakes, while Northern Europe registers higher intakes.
Researchers used advanced mass spectrometry technology to create a molecular model that can aid in designing new osteoporosis treatments. The study's findings provide insights into the structure of a key receptor regulating calcium levels, paving the way for more effective and safer therapies.
The European Menopause and Andropause Society recommends a daily calcium intake of 700-1200mg for postmenopausal women to reduce the risk of osteoporosis. Calcium-rich foods should be prioritized over supplements, as excessive intake may cause harm.
Long-term treatment of osteoporosis is crucial for postmenopausal women to reduce fracture risk. New guidelines recommend reevaluating fracture risk after 3-5 years of bisphosphonate treatment and considering alternative therapies or continued treatment.
Researchers are developing a 'lab-on-a-chip' platform to study cellular communication in bone remodeling, aiming to improve our understanding of bone health and disease. The platform could also be used to test medications meant to halt bone loss, offering a potential solution for osteoporosis and related conditions.
A new treatment for osteoporosis has shown significant improvements in bone density and fracture protection. The study found that romosozumab reduced the risk of vertebral fractures by 48% and clinical fractures by 27%, offering better protection against fractures for high-risk patients.
A study found that less than half of detectable vertebral fractures are reported by radiologists, particularly in non-musculoskeletal radiologists. This under-reporting can lead to delayed diagnosis and treatment of osteoporosis, increasing the risk of future hip fractures.
A new Australian study reveals hip fractures are a major public health issue with high morbidity and mortality rates. The research found that individuals with hip fractures were 3.5 times more likely to die within 12 months compared to non-injured counterparts, with excess mortality risk higher in males than females.
A massive genetic study has identified 153 new gene variants linked to osteoporosis, which could lead to the development of a new treatment. The study found that removing a strongly implicated gene GPC6 in animal models resulted in increased bone thickness.
Researchers at the University of British Columbia have developed a new osteoporosis treatment using a compound derived from red sage, selectively blocking Cathepsin K enzyme activity in bone tissue. This approach may prevent negative side effects associated with current treatments.
Researchers discovered a causal link between senescent cells and age-related bone loss in mice. Targeting these cells increased bone mass and strength. The study's findings suggest that senolytic drugs may have widespread application in treating multiple chronic diseases, including osteoporosis.
Teriparatide therapy increases osteoblast activity and lifespan, but stopping treatment leads to increased fat cell formation in mice. This suggests therapies targeting parathyroid hormone receptors may prioritize osteoblast development over other cell fates.
A study by Cornell University researchers found that prolonged bisphosphonate use can alter the composition of bone, making it more brittle and susceptible to fractures. The study suggests that long-term treatment beyond FDA recommendations may increase the risk of atypical femoral fractures.
A UTA professor has received a grant to design a biomedical device that stimulates bone growth and could be used to treat osteoporosis. The device aims to strengthen bones of people with low bone mass conditions.